Bandwidth Inc vs Zimmer Biomet Holdings Inc — how do they compare? Bandwidth Inc trades at $76.49 (market cap $2.36B), while Zimmer Biomet Holdings Inc trades at $91.11 (market cap $17.61B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 7.5× Bandwidth Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.05% dividend while Bandwidth Inc pays none. Which is the better fit depends on your goals.
| BAND | ZBH | |
|---|---|---|
Market Cap | $2.36B | $17.61B |
Sector | Technology | Health |
52-Week High | $78.44 | $107.71 |
52-Week Low | $12.82 | $79.58 |
Enterprise Value | $2.74B | $24.66B |
Dividend Yield | — | 1.05% |
Signals from Pluang's Aura AI — not financial advice
Bandwidth (BAND) trades at $73.81, down 2.21% today, with strong technical momentum indicated by bullish moving averages. The company reported Q1 2026 EPS of $0.38, beating expectations of $0.32, while revenue reached $753.82 million in 2025. Analyst sentiment is positive with 12 buy ratings and a consensus price target of $71.67. Recent news highlights AI-driven growth in cloud communications and a $275 million convertible notes offering to fuel expansion.
The outlook for BAND is cautiously optimistic, driven by AI infrastructure demand and cloud communications growth. Key risks include negative profit margins and high valuation multiples. Investment opportunity lies in execution of AI initiatives, but investors should monitor earnings sustainability and competitive pressures in the technology sector.
Zimmer Biomet (ZBH) trades at $94.08, up 3.0% in the past 24 hours, near its consensus price target of $97.67. The stock shows bullish technical signals with strong moving average support and has consistently beaten earnings estimates in recent quarters. Revenue grew to $8.23B in 2025, though net income margin declined to 8.56%. Recent corporate developments include expansion in Asia Pacific and a planned $1 billion share repurchase program in 2026.
ZBH presents a balanced outlook with steady revenue growth and shareholder returns via dividends and buybacks, but faces risks from margin compression and rising debt. Analyst sentiment is mixed with 40% buy ratings, suggesting moderate upside potential with caution around profitability trends and competitive pressures in the medical device sector.
Trailing returns across standard periods
Latest headlines on both assets
Bandwidth is a global communications software company. Its CPaaS platform allows enterprises to embed voice, messaging, and 911 emergency services directly into their software applications via robust APIs.
Read more on BAND →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →